PATENT CLAIM ANALYSIS

Application Number: 15950042
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["424", "093730"]

Abstract:
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.

Claim (Index 127):
The method of  claim 126 , wherein the patient after the administration of cyclophosphamide and fludarabine exhibits an increased serum concentration, compared to the serum concentration level prior to the administration of cyclophosphamide and fludarabine, of IL-10, IL-5, IP-10, MCP-1, PLGF, CRP, sICAM-1, or any combination thereof.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 91.0
- Lexical Diversity: 1.6
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15649369', '15167977', '14680860', '14996953', '14918451']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.784514280549625
- 35 USC 102 Novelty (BERT): 0.6273223064333273
- Combined Prediction Score: 0.7687950831379953
- Mean Citation Score: 486.130018
- Max Citation Score: 702.39386
- Similarity Product: 509.87184374957087

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test